Skip to main content
Journal of Biomedicine and Biotechnology logoLink to Journal of Biomedicine and Biotechnology
. 2001;1(1):1–2. doi: 10.1155/S1110724301000018

Journal of Biomedicine and Biotechnology

Jean Dausset
PMCID: PMC102137  PMID: 12488617

PROFESSOR JEAN DAUSSET'S EDITORIAL IN ENGLISH

Why a new medical journal? Why especially this new journal? What are its ambitions? What audience can it reach? Specialists, generalists or both simultaneously? It is intended to be a link between the international scientific community, in particular within the fields of life science and its technological application.

There is undoubtedly a niche to be occupied, an important role to be played to better link this community. I am delighted by the initiative taken by the promoters of this journal, who had the courage to enter the competitive field of scientific journals and to launch an exciting intellectual adventure.

For my part, I would like to briefly broach some medical questions that are dear to me, and that are sufficiently general to be the subject of an editorial.

Where indeed is medical practice going and what does the medicine of tomorrow hold for us? We have watched, amazed, the fantastic advances that are progressively entering current medical practice. The revolution we have witnessed has names, in particular: vaccination, developed by Pasteur, which still has new fields to conquer (until now there is no vaccine against malaria or against AIDS!). There is also antibiotic therapy, exploited to full advantage but beginning to run out of steam, showing its limitations because of the rapid rise of resistant microorganisms. It is only a few decades since developments in immunology have allowed the transplantation of organs or bone marrow. Transplantation—an old dream of humanity finally realized—whose successes themselves have led to many disappointments among the very many patients on the waiting lists, because of the shortage of the organs to be transplanted. It is nevertheless admirable that, in the whole world, 6 million individuals are ready to give their marrow to save patients, in particular those with leukemia. To this list of successes we should add the many victories in oncology due to improved monitoring of tumorigenic agents? And finally, we must not forget the methods of biological investigation and medical imaging, which have seen great improvements recently.

This panorama would be quite incomplete if I did not add the spectacular rise of medical genetics, which makes it possible to locate and to clone the genes responsible for many monogenic diseases and, in the near future, the genes that act in concert to produce the many polygenic diseases that afflict our industrialized societies.

Provided with this arsenal, the doctor, who is a specialist or general practitioner, can from now on offer to his patients increasingly effective therapies, often leading to the cure or amelioration of chronic diseases. Longevity continues to increase each year in the industrialized countries. It should be the same everywhere.

I initiated, many years ago, the concept of predictive medicine, based on frequent associations between some diseases and the alleles of genes of the HLA system. For example ankylosing spondylitis, associated with HLA-B27, or insulin dependent diabetes, associated with HLA-DR3/DR4. This concept has now been extended to the entire human genome and the number of genes of susceptibility to (or protection from) many diseases can only increase. Apart from the HLA system, we know of susceptibility to familial breast cancer, given by genes such as BRCA1 and BRCA2. This idea can only grow in importance, but there is a danger. There can be no question of detection of susceptibility genes without simultaneous development of a preventive or therapeutic counterpart. We should not, under any circumstances, warn a healthy person of an uncertain future, because in this case—and I emphasize this point—we are dealing with a risk of uncertain proportions, without a corresponding method of prevention or cure. It would be unforgivable to cause useless anxiety.

Whatever reservations we might have, the future direction is now clear. There are more and more specialties where tests of increased susceptibility to disease exist. These must be used for the benefit of the patient and not to his detriment.

The physician of the 21st century, if he or she applies these new concepts with prudence, could become the adviser of healthy patients, who are no longer ill. Each person will be able to manage his health capital, as he manages his banking capital; with full knowledge, guided by his doctor, of the developments of modern genetics.

Is it not interesting to note that medicine was, in its history, first of all curative, then preventive and finally predictive, whereas today the order is reversed: initially predictive, then preventive and finally, only in desperation, curative?

Professor Jean Dausset

Nobel Laureate


Articles from Journal of Biomedicine and Biotechnology are provided here courtesy of Wiley

RESOURCES